Free tool · No account
Clinical trials for sarcoma
Sarcoma is a family of rare cancers with many distinct subtypes, and trials are usually subtype-specific. Naming the exact sarcoma type is the single most useful detail.
567 recruiting trials. Showing a sample.
- recruitingNANCT06753136
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneou...
Listed by the study for Retroperitoneal Sarcoma. Record updated 2026-04-13.
Sponsored by Istituto Oncologico Veneto IRCCSFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06333314
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite instability (MSI) non-resectable metastatic or locally adv...
Listed by the study for Soft Tissue Sarcoma. Record updated 2025-12-02.
Sponsored by UNICANCERFull details on ClinicalTrials.gov → - recruitingPhase 1NCT05735184
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC)...
Listed by the study for Myeloid Sarcoma. Record updated 2026-03-13.
Sponsored by Kura Oncology, Inc.Full details on ClinicalTrials.gov → - recruitingNCT07883798
Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
OLIGYNE-10 RT is an international registry of adults with gynecologic cancer and a limited number of active sites of cancer spread who receive radiotherapy (RT) to at least one metastatic lesion during routine care. The registry combines information from existing medical recor...
Listed by the study for Uterine Sarcoma. Record updated 2026-10-23.
Sponsored by Affidea Nu-med Center of Oncological DIagnostics and TherapyFull details on ClinicalTrials.gov → - recruitingNCT04557969
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Objective: To follow people with GISTs and collect tumor tissue so that it can be studied in the lab. Eligibility: People age 6 and older who have a GIST. Design: Participants will be screened with a review of their medical records and samples. Participants will enroll i...
Listed by the study for Gastrointestinal Stromal Sarcoma. Record updated 2026-11-09.
Sponsored by National Cancer Institute (NCI)Full details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT01659203
Proton or Photon RT for Retroperitoneal Sarcomas
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational intervention. Phase I studies also try to define the appropriate dose of the investigational therapy to use for further studies. "Investigational" means that the inte...
Listed by the study for Retroperitoneal Sarcoma. Record updated 2026-07-31.
Sponsored by Massachusetts General HospitalFull details on ClinicalTrials.gov → - recruitingPhase 2NCT07308886
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Background: Kaposi sarcoma (KS) is a cancer that causes abnormal tissue to grow in the skin, lymph nodes, and other organs. KS is caused by a virus known as Kaposi sarcoma herpesvirus. People infected with human immunodeficiency virus (HIV) account for 80% of KS cases in the ...
Listed by the study for Kaposi Sarcoma. Record updated 2026-08-25.
Sponsored by National Cancer Institute (NCI)Full details on ClinicalTrials.gov → - recruitingNANCT07062003
Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors
This clinical trial tests the safety and best dose of minibeam radiation therapy (MBRT) with a tungsten slit collimator for treating patients with skin or soft tissue tumors that have come back after a period of improvement (recurrent) or that spread from where they first star...
Listed by the study for Sarcoma. Record updated 2026-09-11.
Sponsored by Mayo ClinicFull details on ClinicalTrials.gov → - recruitingPhase 1NCT03721068
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
The body has different ways of fighting infections and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body fr...
Listed by the study for Osteosarcoma. Record updated 2026-03-27.
Sponsored by UNC Lineberger Comprehensive Cancer CenterFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-11-14. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this sarcoma trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.